EUCTR2004-001896-21-FI进行中（未招募）不适用
A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study toEvaluate the Safety and Immunogenicity of Chiron Meningococcal ACWY ConjugateVaccine in Healthy Children Aged 12-59 Months
Chiron S.r.l.0 个研究点目标入组 600 人开始时间: 2004年9月17日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. healthy 12-<60 month old children;
- •2. for whom a parent/legal guardian has given written informed consent after the
- •nature of the study has been explained;
- •3. available for all the visits scheduled in the study;
- •4. in good health as determined by:
- •medical history
- •physical examination
- •clinical judgment of the investigator.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Children who should not be enrolled in the study are those:
- •1.whose parents/legal guardians are unwilling or unable to give written informed consent to participate in the study;
- •2.who have previously received any meningococcal vaccine;
- •3.who have a previous ascertained or suspected disease caused by N. meningitidis;
- •4.who have had household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection;
- •5.who have a history of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component;
- •6.who have experienced significant acute or chronic infection within the previous 7 days or have experienced fever (axillary temperature =38.0°C or rectal temperature =38.5°C) within 3 days previous to immunization;
- •7.who have any present or suspected serious acute (e.g. leukemia, lymphomas), or chronic disease (e.g., with signs of cardiac, renal failure, or severe malnutrition or insulin dependent diabetes), or progressive neurological disease, or a genetic anomaly/known cytogenic disorders (e.g., Down’s syndrome)
- •8.who have received another vaccine within the past 30 days from first or second immunization or any blood draw
- •9.who have received any investigational agent (including vaccine) within the past 90 days from first or second immunization or any blood draw
- •10.who have a known or suspected autoimmune disease or impairment /alteration of immune function resulting from (for example):
- •a)administration of any immunosuppressive therapy
- •b)administration of any immunostimulants
- •c)administration of any sytemic corticosteroid administered for more than 4 days in the previous 30 days
- •11.with a suspected or known HIV infection or HIV related disease;
- •12.who have ever received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation;
- •13.with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding;
- •14.who have a history of any seizure disorder;
- •15.who have taken systemic antibiotics (either oral or parenteral) within the previous 14 days (EXCEPTION: subjects who have received an oral or parenteral ß-lactam antibiotic [examples: penicillin, amoxicillin, ceftriaxone, cefuroxime, cephalexin, etc.] may be enrolled 7 days following the last dose of antibiotic);
- •16.who with their parents/legal guardians are planning to leave the area of the study site before the end of the study period;
- •17.with any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
研究者
相似试验
进行中（未招募）
不适用
Immune Response Induced by a Trivalent Group B strep. vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings.Prophylaxis against Group B Streptococcus infection.EUCTR2010-020840-36-Outside-EU/EEAovartis Vaccines and Diagnostics100
进行中（未招募）
1 期
Testing a vaccine in pregnant woman to protect their newborn babies from blood poisoning caused by a bacteriumInvasive group B streptococcus diseaseMedDRA version: 13.1Level: PTClassification code 10053588Term: Group B streptococcus neonatal sepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-020840-36-BEovartis Vaccines and Diagnostics GmbH100
进行中（未招募）
不适用
Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months.InfluenzaEUCTR2014-004543-12-Outside-EU/EEAovartis Vaccines and Diagnostics Srl.350
进行中（未招募）
不适用
Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years oldHealthy volunteers (immunization against A/California/7/2009 (H1N1)v-like influenza)MedDRA version: 18.0Level: LLTClassification code 10073988Term: Bird fluSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10021433Term: ImmunizationSystem Organ Class: 100000004865EUCTR2011-003512-23-Outside-EU/EEAGlaxoSmithKline Biologicals209
进行中（未招募）
1 期
Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV vaccine (GSK-580299) and Merck's Gardasil® vaccine when administered according to alternative 2-dose schedules in 9-14 years old femalesCervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic human papillomaviruses (HPV).MedDRA version: 14.0Level: LLTClassification code 10033723Term: Papilloma viral infection NOSSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056576Term: Cervical intraepithelial neoplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2011-002035-26-FRGlaxoSmithKline Biologicals1,079